Effect of myeloid specific Trem2 knockout in hepatocellular carcinoma after anti-PD-1 therapy [ChIP-seq]

Immune-checkpoint blockade (ICB) therapies have transformed the treatment landscapes of solid malignancies, including hepatocellular carcinoma (HCC), which is currently the sixth most common cancer and the third leading cause of cancer death worldwide. Despite unprecedented success in clinical trials, the immunosuppressive tumor microenvironment constructed by tumor cells restricts the responsiveness of ICB therapies to a minority of patients. Triggering receptor expressed on myeloid cells-2 (TREM2) counteracts inflammation and maintains metabolic fitness in myeloid cells. Emerging single-cell RNA sequencing data in different types of tumors have identified the significance of TREM2+ myeloid cells in tumor development and ICB resistance. In this study, we aimed to investigate the potential role of TREM2 in HCC ICB resistance.